Emerging drugs for diabetic retinopathy

Bibliography

• Bandello F, Battaglia PM, Lanzetta P, Diabetic macular edema in Coscas G. Macular Edema Dev Ophthalmol 2010;47:73-110
   PubMedGoogle Scholar
• Bandello F, and CO-Authors, Macular Edema Book
   Google Scholar
• Girach A, Lund-Andersen H. Diabetic macular oedema: a clinical overview. Int J Clin Prac 2007;61:88-97
   PubMed Web of Science ®Google Scholar
• Johnson M. Perspective - Etiology and treatment of macular edema. Am J Ophthalmol 2009;147:11
   PubMed Web of Science ®Google Scholar
• Rotsos TG, Moschos MM. Cystoid macular edema. Clin Ophthalmol 2008;2:919-30
   PubMedGoogle Scholar
• A.J. Augustin, Augenheilkunde. 3 Auflage
   Google Scholar
• Augustin AJ. Upcoming therapeutic advances in diabetic macular edema: an intravitreal dexamethasone drug delivery system. Expert Opin 2011;8:271-9
   Google Scholar
• Bandello F, Polito A, Del Borrello M, “Light” versus “classic” laser treatment for clinically significant diabetic macular oedema. Br J Ophthalmol 2005;89:864-70
   PubMed Web of Science ®Google Scholar
• Lanzetta P, Polito A, Veritti D. Subthreshold laser. Ophthalmology 2008;115:216-216.e1
   PubMed Web of Science ®Google Scholar
• Luttrull JK, Spink CJ. Serial optical coherence tomography of subthreshold diode laser micropulse photocoagulation for diabetic macular edema. Ophthalmic Surg Lasers Imaging 2006;37:370-7
   PubMed Web of Science ®Google Scholar
• Sivaprasad S, Sandhu R, Tandon A, Subthreshold micropulse diode laser photocoagulation for clinically significant diabetic macular oedema: a three-year follow up. Clin Experiment Ophthalmol 2007;35:640-4
   PubMed Web of Science ®Google Scholar
• Audren F, Erginay A, Haouchine B, Intravitreal triamcinolone acetonide for diffuse macular oedema: 6-month results of a prospective controlled trial. Acta Ophthalmol Scand 2006;84:624-30
   PubMedGoogle Scholar
• Jonas JB, Kamppeter BA, Harder B, Intravitreal triamcinolone acetonide for diabetic macular edema: a prospective, randomized study. J Ocul Pharmacol Ther 2006;22:200-7
   PubMed Web of Science ®Google Scholar
• Gillies MC, Sutter FK, Simpson JM, Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology 2006;113:1533-8
   PubMed Web of Science ®Google Scholar
• Hauser D, Bukelman A, Pokroy R, Intravitreal triamcinolone for diabetic macular edema: comparison of 1, 2, and 4 mg. Retina 2008;28:825-30
   PubMed Web of Science ®Google Scholar
• Kim JE, Pollack JS, Miller DG, ISIS-DME: a prospective, randomized, dose-escalation intravitreal steroid injection study for refractory diabetic macular edema. Retina 2008;28:735-40
   PubMed Web of Science ®Google Scholar
• Beer PM, Bakri SJ, Singh RJ, Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection. Ophthalmology 2003;110:681-6
   PubMed Web of Science ®Google Scholar
• Audren F, Tod M, Massin P, Pharmacokinetic-pharmacodynamic modeling of the effect of triamcinolone acetonide on central macular thickness in patients with diabetic macular edema. Invest Ophthalmol Vis Sci 2004;45:3435-41
   PubMed Web of Science ®Google Scholar
• Elman MJ, Raden RZ, Sloan MD, Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabeticmacular edema. Ophthalmology 2008;115:1447-9
   PubMed Web of Science ®Google Scholar
• Gillies MC, McAllister IL, Zhu M, Intravitreal triamcinolone prior to laser treatment of diabetic macular edema: 24-month results of a randomized controlled trial. Ophthalmology 2011;118:866-72
   PubMed Web of Science ®Google Scholar
• Jonas JB, Kreissig I, Degenring R. Intraocular pressure after intravitreal injection of triamcinolone acetonide. Br J Ophthalmol 2003;87:24-7
   PubMed Web of Science ®Google Scholar
• Moshfeghi DM, Kaiser PK, Scott IU, Acute endophthalmitis following intravitreal triamcinolone acetonide injection. Am J Ophthalmol 2003;136:791-6
   PubMed Web of Science ®Google Scholar
• Massin P, Bandello F, Garweg JG, Safety and Efficacy of Ranibizumab in diabetic macular edema (RESOLVE Study). Diabetes Care 2010;33:2399-405
   PubMed Web of Science ®Google Scholar
• Williams GA. The economic burden of diabetic macular edema cost-effectiveness of therapy is a complex equation. Retina Today 2009;1-4
   Google Scholar
• Rein DB, Zhang P, Wirth K, The economic burden of major adult visual disorders in the United States. Arch Ophthalmol 2006;124:1754-60
   PubMed Web of Science ®Google Scholar
• Shea AM, Curtis LH, Hammill BG, Resource use and costs associated with diabetic macular edema in elderly persons. Arch Ophthalmol 2008;126:1748-54
   PubMed Web of Science ®Google Scholar
• Sharma S, Hussein H, Brown GC, The cost-effectiveness of grid laser photocoagulation for the treatment of diabetic macular edema: results of a patient-based cost-utility analysis. Curr Opin Ophthalmol 2000;11:175-9
   PubMedGoogle Scholar
• Smiddy WE. Economic considerations of macular edema therapies. Ophthalmology 2011;118:1827-33
   PubMed Web of Science ®Google Scholar
• Martidis A, Duker JS, Greenberg PB, Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology 2002;109:920-7
   PubMed Web of Science ®Google Scholar
• Rudinsky CJ, Lavergne V, Katz D. Visual acuity after intravitreal triamcinolone for diabetic macular edema refractory to laser treatment: a meta-analysis. Can J Ophthalmol 2009;44:587-93
   PubMed Web of Science ®Google Scholar
• Fachinformation Ozurdex 2010
   Google Scholar
• Joussen AM, Poulaki V, Le ML, A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J 2004;18:1450-2
   PubMed Web of Science ®Google Scholar
• Aiello LP. Vascular endothelial growth factor and the eye: biochemical mechanisms of action and implications for novel therapies. Ophthalmic Res 1997;29:354-62
   PubMed Web of Science ®Google Scholar
• Ferrara N. Role of vascular endothelial growth factor in the regulation of angiogenesis. Kidney Int 1999;56:794-814
   PubMed Web of Science ®Google Scholar
• Abelson MB, Butrus S. Corticosteroids in ophthalmic practice. In: Abelson MB, Neufeld AH, Topping TM, editors. Principles and practice of ophthalmology. W.B. Saunders; Philadelphia, PA: 1994. p. 1014
   Google Scholar
• Kragballe K. Topical corticosteroids; mechanisms of action. Acta Derm Venereol Suppl 1989;151:7-10
   PubMedGoogle Scholar
• Amsterdam A, Tajima K, Sasson R, Cell-specific regulation of apoptosis by glucocorticoids: implication to their anti-inflammatory action. Biochem Pharmacol 2002;64:843-50
   PubMed Web of Science ®Google Scholar
• Tamura H, Miyamoto K, Kiryu J, Intravitreal injection of corticosteroids attenuates leukostasis and vascular leakage in experimental diabetic retina. Invest Ophthalmol Vis Sci 2005;46:1440-4
   PubMed Web of Science ®Google Scholar
• Itakura H, Akiyama H, Hagimura N, Triamcinolone suppresses interleukin-1beta-mediated increase in vascular endothelial growth factor expression in cultured rat muller cells. Graefes Arch Clin Exp Ophthalmol 2006;244:226-31
   PubMed Web of Science ®Google Scholar
• Nauck M, Roth M, Tamm M, Induction of vascular endothelial growth factor by platelet-activating factor and platelet-derived growth factor is down-regulated by corticosteroids. Am J Respir Cell Mol Biol 1998;16:398-406
   Web of Science ®Google Scholar
• Edelman JL, Lutz D, Castro MR. Corticosteroids inhibit VEGF-induced vascular leakage in a rabbit model of blood-retinal and blood-aqueous barrier breakdown. Exp Eye Res 2005;80:249-58
   PubMed Web of Science ®Google Scholar
• Gardner TW, Antonetti DA, Barber AJ, Diabetic retinopathy: more than meets the eye. Surv Ophthalmol 2002;47(Suppl 2):S253-62
   PubMed Web of Science ®Google Scholar
• Grant MB, Afzal A, Spoerri P, The role of growth factors in the pathogenesis of diabetic retinopathy. Expert Opin Investig Drugs 2004;13:1275-93
   PubMed Web of Science ®Google Scholar
• Hsu J. Drug delivery methods for posterior segment disease. Curr Opin Ophthalmol 2007;18:235-9
   PubMed Web of Science ®Google Scholar
• Kearns VR, Williams RL. Drug delivery systems for the eye. Expert Rev Med Devices 2009;6:277-90
   PubMed Web of Science ®Google Scholar
• Iluvien, an innovative treatment for diabetic Macular Edema. Alimera Sciences. Available from: www. alimerasciences.com/Products/IluvienOverview/tabid/82/Default.aspx [Last accessed 26 September 2010]
   Google Scholar
• Schwartz SG, Flynn HW. Pharmacotherapies for diabetic retinopathy: present and future. Exp Diabetes Res 2007; published online 22 March 2007; doi:10.1155/2007/52487
   PubMedGoogle Scholar
• Campochiaro PA. Data from FAME phase 3 study for Iluvien presented at Angiogenesis 2010. Available from: http://www.news-medical.net/news/20100304/Data-from-FAME-Phase-3- study-for-Iluvien-presented-at-Angiogenesis-2010.aspx
   Google Scholar
• Clinical trials.gov. Efficacy of Fluocinolone Acetonide Intravitreal Implant in Diabetic Macular Edema. Available from: www.clinicaltrials.gov/ct2/show/NCT00502541 [Last accessed 27 September 2010]
   Google Scholar
• Kuppermann BD. Steroid implant overview: I-vation TA, Posurdex, Iluvien, and more. Paper presented at the American Academy of Ophthalmology; San Francisco: 2009
   Google Scholar
• Ingerman A, Dewey-Mattia D. Emerging treatments for diabetic macular edema. Retina Today 2010;8:52-4
   Google Scholar
• Clinical Trials. gov. A Study of MK0140 in Diabetic Patients With Macular Edema. Available from: www.clinicaltrials.gov/ct2/show/NCT00692614
   Google Scholar
• Haller JA, Dugel P, Weinberg DV, Evaluation of the safety and performance of an applicator for a novel intravitreal dexamethasone drug delivery system for the treatment of macular edema. Retina 2009;29:46-51
   PubMed Web of Science ®Google Scholar
• Chang-Lin JE, Attar M, Acheampong AA, Pharmacokinetics and pharmacodynamics of the sustained-release dexamethasone intravitreal implant. Invest Ophthalmol Vis Sci 2011;52:80-6
   PubMed Web of Science ®Google Scholar
• Lee SS, Hughes PM, Robinson MR. Recent advances in drug delivery systems for treating ocular complications of systemic diseases. Curr Opin Ophthalmol 2009;20:511-19
   PubMed Web of Science ®Google Scholar
• Kuppermann BD, Loewenstein A. Drug delivery to the posterior segment of the eye in Coscas G. Macular Edema. Dev Ophthalmol 2010;47:59-72
   PubMedGoogle Scholar
• Elman MJ, Aiello LP, Beck RW, The Diabetic Retinopathy Clinical Research Network. Randomized trial evaluating ranibizumab plus prompt or deferred laser or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2010;117:1064-77
   PubMed Web of Science ®Google Scholar
• Kuppermann BD, Blumenkranz MS, Haller JA, Dexamethasone DDS Phase II Study Group: randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch Ophthalmol 2007;125:309-17
   PubMed Web of Science ®Google Scholar
• Haller JA, Kuppermann BD, Blumenkranz MS, Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema. Arch Ophthalmol 2010;128:289-96
   PubMed Web of Science ®Google Scholar
• Kuppermann BD, Chou C, Weinberg DV, Intravitreous dexamethasone effects on different patterns of diabetic macular edema. Arch Ophthalmol 2010;128:642-3
   PubMed Web of Science ®Google Scholar
• Boyer DS, Faber D, Gupta S, Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patients. Retina 2011;31:915-23
   PubMed Web of Science ®Google Scholar
• Yanyali A, Nohutcu AF, Horozoglu F, Modified grid laser photocoagulation versus pars plana vitrectomy with internal limiting membrane removal in diabetic macular edema. Am J Ophthamol 2005;139:795-801
   PubMed Web of Science ®Google Scholar
• Schindler RH, Chandler D, Thresher R, The clearance of intravitreal triamcinolone acetonide. Am J Ophthamol 1982;93:415-17
   PubMed Web of Science ®Google Scholar
• Chin HS, Park TS, Moon YS, Difference in clearance of intravitreal triamcinolone acetonide between vitrectomized and nonvitrectomized eyes. Retina 2005;25:556-60
   PubMed Web of Science ®Google Scholar
• Beer PM, Bakri SJ, Singh RJ, Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection. Ophthalmology 2003;110:681-6
   PubMed Web of Science ®Google Scholar
• Clinical Trials.gov. A Study of the Safety and Efficacy of a New Treatment for Diabetic Macular Edema. Clinical. Available from: www.clinicaltrials.gov/ct2/show/NCT00168389
   Google Scholar
• Clinical Trials.gov. A Study of the Safety and Efficacy of a New Treatment for Diabetic Macular Edema. Clinical. Available from: www.clinicaltrials.gov/ct2/show/NCT00168337
   Google Scholar
• Clinical trials.gov. Safety and Efficacy of New Treatment in Combination With Laser for Diabetic Macular Edema. Available from: http://clinicaltrials.gov/ct2/show/NCT00464685
   Google Scholar
• Massin PG. Ranibizumab indiabetic macular edema. Joint Meet Am Acad Ophthalmol Eur Soc Ophthalmol; Atlanta: 2008
   Google Scholar
• Mitchell P, Bandello F, Schmidt-Erfurth U, The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 2011;118:615-25
   PubMed Web of Science ®Google Scholar
• Elman MJ, Bressler NM, Qin H, Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2011;118:609-14
   PubMed Web of Science ®Google Scholar
• Gooqe J, Brucker AJ, Bressler NM, Randomized trial evaluating short-term effects of intravitreal Ranibizumab or Triamcinolone Acetonide on macular edema after focal/grid laser for diabetic macular edema in eyes also receiving panretinal photocoagulation. Retina 2011;31:1009-27
   PubMed Web of Science ®Google Scholar
• Ozturk BT, Kerimoglu H, Adam M, Glucose regulation influences treatment outcome in ranibizumab treatment for diabetic macular edema. J Diabetes Complications 2011;25:298-302
   PubMed Web of Science ®Google Scholar
• Clinical trials.gov. A Study of Ranibizumab Injection in Subjects With Clinically Significant Macular Edema With Center Involvement Secondary to Diabetes Mellitus (RISE). Available from: http://clinicaltrials.gov/ct2/show/NCT00473330
   Google Scholar
• Clinical trials.gov. A Study of Ranibizumab Injection in Subjects With Clinically Significant Macular Edema With Center Involvement Secondary to Diabetes Mellitus (RIDE). Available from: http://clinicaltrials.gov/ct2/show/NCT00473382
   Google Scholar
• Sultan MB, Zhou D, Loftus J, A phase 2/3, multicenter, randomized, double-masked, 2-year trial of pegaptanib sodium for the treatment of diabetic macular edema. Ophthalmology 2011;118:1107-18
   PubMed Web of Science ®Google Scholar
• Clinical trials.gov. Study To Evaluate Safety And Tolerability Of Pegaptanib Sodium In Patients With Diabetic Macular Edema. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01189461
   Google Scholar
• Do DV, Schmidt-Erfurth U, Gonzalez VH, The DA VINCI Study: phase 2 primary results of VEGF trap-eye in patients with diabetic macular edema. Ophthalmology 2011;118:1819-26
   PubMed Web of Science ®Google Scholar
• Clinical trials.gov; VEGF Trap-Eye in Vision Impairment Due to DME (VIVID-DME). Available from: http://www.clinicaltrials.gov/ct2/show/NCT01331681
   Google Scholar
• Kelly DJ, Zhang Y, Hepper C, Protein Kinase C B inhibition attenuates the progression of experimental diabetic nephropathy in the presence of continued hypertension. Diabetes 2003;52:512-18
   PubMed Web of Science ®Google Scholar
• Ishii H, Jirousek MR, Koya D, Amelioration of vascular dysfunctions in diabetic rats by an oral PKC inhibitor. Science 1996;272:728-31
   PubMed Web of Science ®Google Scholar
• Aiello LP, Vignati L, Sheetz MJ, ORAL PROTEIN KINASE C beta INHIBITION USING RUBOXISTAURIN: Efficacy, Safety, and Causes of Vision Loss Among 813 Patients (1,392 Eyes) with Diabetic Retinopathy in the Protein Kinase C beta Inhibitor-Diabetic Retinopathy Study and the Protein kinase C beta Inhibitor-Diabetic Retinopathy Study 2. Retina 2011;31:2084-94
   PubMed Web of Science ®Google Scholar
• Pruneau D, Belichard P, Sahel JA, Targeting the kallikrein-kinin system as a new therapeutic approach to diabetic retinopathy. Curr Opin Investig Drugs 2010;11:507-14
   PubMed Web of Science ®Google Scholar
• Clinical trials.gov. Safety and Efficacy Study of Topical Administration of FOV2304 (High Dose or Low Dose) for the Treatment of Center-involving Clinically Significant Macular Edema Associated With Diabetic Retinopathy. Available from: http://clinicaltrials.gov/ct2/show/NCT01319487
   Google Scholar
• Ai M, Yoshida M. Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Nihon Rinsho 2010;68(Suppl 9):285-90
   PubMedGoogle Scholar
• Mohammad DA, Sweet BV, Elner SG. Retisert: is the new advance in treatment of uveitis a good one? Ann Pharmacother 2007;41:449-54
   PubMed Web of Science ®Google Scholar
• Kane FE, Burdan J, Cutino A, Iluvien: a new sustained delivery technology for posterior eye disease. Expert Opin Drug Deliv 2008;5:1039-46
   PubMed Web of Science ®Google Scholar
• Barnett PJ. Mathematical modeling of triamcinolone acetonide drug release from the I-vation intravitreal implant (a controlled release platform). Conf Proc IEEE Eng Med Biol Soc 2009;2009:3087-90
   PubMedGoogle Scholar
• Haller JA, Dugel P, Weinberg DV, Evaluation of the safety and performance of an applicator for a novel intravitreal dexamethasone drugs delivery system for the treatment of macular edema. Retina 2009;29:46-51
   PubMed Web of Science ®Google Scholar
• Van der Reis MI, La Heij EC, De Jong-Hesse Y, A Systematic review of the adverse events of intravitreal anti-vascular endothelial growth factor injections. Retina 2011;31:1449-69
   PubMed Web of Science ®Google Scholar
• Medical news today: NICE Turns Down Lucentis (Ranibizumab) For Diabetic Macular Edema Treatment UK, from Christian Nordqvist. Available from: http://www.medicalnewstoday.com/articles/231180.php
   Google Scholar
• Nice.org.UK. Ranibizumab for the treatment of diabetic macular oedema. Available from: http://guidance.nice.org.uk/TA/Wave23/30
   Google Scholar
• Waisbourd M, Goldstein M, Loewenstein A. Treatment of diabetic retinopathy with anti-VEGF drugs. Acta Ophthalmol 2011;89:203-7
   PubMed Web of Science ®Google Scholar
• Arevalo JF, Sanchez JG, Lasave AF, Intravitreal Bevacizumab (Avastin) for Diabetic Retinopathy: The 2010 GLADAOF Lecture. J Ophthalmol 2011;2011:584238
   PubMedGoogle Scholar
• Smith JM, Steel DH. Anti-vascular endothelial growth factor for prevention of postoperative vitreous cavity haemorrhage after vitrectomy for proliferative diabetic retinopathy. Cochrane Database Syst Rev 2011;11:CD008214
   Google Scholar